Zydus Lifesciences Ltd. - Research Center
532321 ZYDUSLIFE Group (A) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Mar' 24 | Dec' 23 | Sep' 23 | Jun' 23 | Mar' 23 | |
|---|---|---|---|---|---|
| Sales | 3,332.40 | 2,371.30 | 2,159.30 | 2,955.70 | 2,579.30 |
| Operating profit | 1,569.20 | 699.10 | 649.40 | 1,141.00 | 772.50 |
| Interest | 106.20 | 103.90 | 90.90 | 89.70 | 85.00 |
| Gross profit | 1,824.10 | 702.00 | 1,093.00 | 1,133.70 | 938.70 |
| EPS (Rs) | 13.97 | 4.45 | 7.95 | 7.72 | 4.85 |
Quarterly
results in details
| Mar' 24 | Dec' 23 | Sep' 23 | Jun' 23 | Mar' 23 | |
|---|---|---|---|---|---|
| Other income | 361.10 | 106.80 | 534.50 | 82.40 | 251.20 |
| Stock adjustment | -86.20 | 24.50 | -98.10 | 28.10 | -14.70 |
| Raw material | 737.20 | 681.60 | 705.90 | 876.70 | 806.70 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 405.10 | 373.00 | 377.70 | 351.70 | 353.10 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 707.10 | 593.10 | 524.40 | 558.20 | 661.70 |
| Provisions made | - | - | - | - | - |
| Depreciation | 130.60 | 127.70 | 124.90 | 121.20 | 119.90 |
| Taxation | 279.70 | 123.90 | 163.10 | 231.60 | 124.30 |
| Net profit / loss | 1,405.20 | 450.40 | 805.00 | 780.90 | 490.70 |
| Extra ordinary item | -8.60 | - | - | - | -203.80 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 100.60 | 101.20 | 101.20 | 101.20 | 101.20 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 47.09 | 29.48 | 30.07 | 38.60 | 29.95 |
| GPM (%) | 49.39 | 28.33 | 40.57 | 37.32 | 33.16 |
| NPM (%) | 38.05 | 18.18 | 29.88 | 25.70 | 17.34 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis